Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Leukemias

Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission

Leukemia volume 21, pages 1700–1707 (2007)Cite this article

Abstract

Acute myeloid leukemia (AML) is generally regarded as a stem cell disease. In CD34-positive AML, the leukemic stem cell has been recognized as CD38 negative. This CD34+CD38− population survives chemotherapy and is most probable the cause of minimal residual disease (MRD). The outgrowth of MRD causes relapse and MRD can therefore serve as a prognostic marker. The key role of leukemogenic CD34+CD38− cells led us to investigate whether they can be detected under MRD conditions. Various markers were identified to be aberrantly expressed on the CD34+CD38− population in AML and high-risk MDS samples at diagnosis, including C-type lectin-like molecule-1 and several lineage markers/marker-combinations. Fluorescent in situ hybridization analysis revealed that marker-positive cells were indeed of malignant origin. The markers were neither expressed on normal CD34+CD38− cells in steady-state bone marrow (BM) nor in BM after chemotherapy. We found that these markers were indeed expressed in part of the patients on malignant CD34+CD38− cells in complete remission, indicating the presence of malignant CD34+CD38− cells. Thus, by identifying residual malignant CD34+CD38− cells after chemotherapy, MRD detection at the stem cell level turned out to be possible. This might facilitate characterization of these chemotherapy-resistant leukemogenic cells, thereby being of help to identify new targets for therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Feller N, van der Pol MA, van Stijn A, Weijers GW, Westra AH, Evertse BW et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004; 18: 1380–1390.

    Article  CAS  PubMed  Google Scholar 

  2. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96: 3948–3952.

    CAS  PubMed  Google Scholar 

  3. San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98: 1746–1751.

    Article  CAS  PubMed  Google Scholar 

  4. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T . Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104: 3078–3085.

    Article  CAS  PubMed  Google Scholar 

  5. Bonnet D, Dick JE . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730–737.

    Article  CAS  PubMed  Google Scholar 

  6. Costello R, Mallet F, Chambost H, Sainty D, Arnoulet C, Gastaut JA et al. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors. Leukemia 1999; 13: 1513–1518.

    Article  CAS  PubMed  Google Scholar 

  7. van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005; 11: 6520–6527.

    Article  CAS  PubMed  Google Scholar 

  8. Jordan CT, Guzman ML, Noble M . Cancer stem cells. N Engl J Med 2006; 355: 1253–1261.

    Article  CAS  PubMed  Google Scholar 

  9. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14: 1777–1784.

    Article  CAS  PubMed  Google Scholar 

  10. Lowenberg B, Downing JR, Burnett A . Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062.

    Article  CAS  PubMed  Google Scholar 

  11. Bakker AB, Van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 2004; 64: 8443–8450.

    Article  CAS  PubMed  Google Scholar 

  12. Lacombe F, Durrieu F, Briais A, Dumain P, Belloc F, Bascans E et al. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 1997; 11: 1878–1886.

    Article  CAS  PubMed  Google Scholar 

  13. van der Pol MA, Feller N, Roseboom M, Moshaver B, Westra G, Broxterman HJ et al. Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica 2003; 88: 983–993.

    PubMed  Google Scholar 

  14. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL . Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003; 17: 3029–3035.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442: 818–822.

    Article  CAS  PubMed  Google Scholar 

  16. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 2001; 98: 1166–1173.

    Article  CAS  PubMed  Google Scholar 

  17. Terstappen LW, Loken MR . Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol 1990; 2: 229–240.

    CAS  PubMed  Google Scholar 

  18. van der Pol MA, Broxterman HJ, Pater JM, Feller N, van der MM, Weijers GW et al. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica 2003; 88: 134–147.

    CAS  PubMed  Google Scholar 

  19. van Stijn A, Kok A, van Stalborch MA, van der Pol MA, Feller N, Westra AH et al. Minimal residual disease cells in AML patients have an apoptosis-sensitive protein profile. Leukemia 2004; 18: 875–877.

    Article  CAS  PubMed  Google Scholar 

  20. Hess CJ, Denkers F, Ossenkoppele GJ, Waisfisz Q, McElgunn CJ, Eldering E et al. Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method. Leukemia 2004; 18: 1981–1988.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledge the Department of Cardiac Surgery and their patients for providing normal bone marrow samples.

Author information

Authors and Affiliations

  1. Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands

    A van Rhenen, B Moshaver, A Kelder, N Feller, S Zweegman, G J Ossenkoppele & G J Schuurhuis

  2. Department of Cytogenetics, VU University Medical Center, Amsterdam, The Netherlands

    A W M Nieuwint

Authors
  1. A van Rhenen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Moshaver
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Kelder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Feller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A W M Nieuwint
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Zweegman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G J Ossenkoppele
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G J Schuurhuis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G J Schuurhuis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Rhenen, A., Moshaver, B., Kelder, A. et al. Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 21, 1700–1707 (2007). https://doi.org/10.1038/sj.leu.2404754

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404754

Keywords

This article is cited by

Search

Advanced search

Quick links